No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
HK Stock MarketDetailed Quotes
810673 Mabwell (Shanghai) Bioscience Co., Ltd
- 0.000
- 0.0000.00%
Market Closed Jan 9 09:30 CST
0Market Cap0.00P/E (TTM)
0.000High0.000Low0Volume0.000Open0.000Pre Close0.00Turnover0.00%Turnover Ratio0.00P/E (Static)0Shares0.00052wk High0.00P/B0Float Cap0.00052wk Low--Dividend TTM0Shs Float0.000Historical High--Dividend LFY0.00%Amplitude0.000Historical Low--Avg Price--Lot Size--Div YieldTTM--Div Yield LFY
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
No Data
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
New stock news | Maiwei Bio has submitted its application to the Hong Kong Stock Exchange, with CITIC and Haitong as co-sponsors.
Maiwei Biotech is a pharmaceutical company primarily focused on the independent development of drugs for tumors and age-related diseases, currently in the commercialization stage.
Sprint A+H! Maiwei Biotech plans to go public in Hong Kong through an IPO, but three products struggle to turn around the deficit situation.
① After nearly 3 years of being listed on the Star, Maiwei Bio plans to go public in Hong Kong, aiming to meet the funding needs of its Operation and to enhance its level of internationalization. ② Currently, Maiwei Bio has 3 commercial products, but the income from these products is insufficient to cover the huge research and development expenses as well as other shipping costs, leaving Maiwei Bio in a serious financial deficit.
Maiwei Biotech's targeted Nectin-4 ADC combined with PD-1 monoclonal antibody has received CDE approval to conduct phase III clinical research for the first-line treatment of urothelial carcinoma.
Shanghai, August 26, 2024 /PR Newswire/ -- Maiwei Biotech (688062.SH), an innovative biopharmaceutical company with a comprehensive Industry Chain layout, announced that its "randomized, controlled, open-label, multicenter Phase III clinical study protocol assessing the combination of 9MW2821 and Toripalimab compared to standard chemotherapy as first-line treatment for locally advanced or metastatic urothelial carcinoma patients" submitted to the National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has been approved, and the combination of 9MW2821 and PD-1 monoclonal antibody for first-line treatment of urothelial carcinoma has been initiated.
Maiwei Biotech (688062.SH) subsidiary signs a licensing agreement with Runjia Pharmaceutical to introduce new products in the field of osteoarthritis treatment.
Maiwei Bio (688062.SH) announced that its wholly-owned subsidiary Jiangsu Taikang Biomedical Co., Ltd. ("Taikang...)
Trending HK Stocks
HK Dividend Stocks HK Dividend Stocks
Dividend stocks are stocks of companies in the HK stock market that regularly distribute dividends to shareholders, generally representing stable businesses. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in HK dividend stocks, ranked from highest to lowest based on real-time market data. Dividend stocks are stocks of companies in the HK stock market that regularly distribute dividends to shareholders, generally representing stable businesses. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in HK dividend stocks, ranked from highest to lowest based on real-time market data.